flumazenil and eszopiclone

flumazenil has been researched along with eszopiclone in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Czajkowski, C; Hanson, SM; Morlock, EV; Satyshur, KA	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Choi, Y; Raymer, BK	1

Reviews

2 review(s) available for flumazenil and eszopiclone

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Sleep modulating agents. Bioorganic & medicinal chemistry letters, 2019, 08-15, Volume: 29, Issue:16 Topics: Animals; Humans; Sleep; Sleep Aids, Pharmaceutical; Sleep Wake Disorders; Wakefulness-Promoting Agents	2019

Other Studies

2 other study(ies) available for flumazenil and eszopiclone

Article	Year
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different. Journal of medicinal chemistry, 2008, Nov-27, Volume: 51, Issue:22 Topics: Azabicyclo Compounds; Benzodiazepines; Binding Sites; Cell Line; Computer Simulation; Cysteine; DNA Mutational Analysis; Eszopiclone; GABA-A Receptor Agonists; Humans; Hydrogen Bonding; Ligands; Models, Chemical; Models, Molecular; Mutagenesis, Site-Directed; Piperazines; Pyridines; Receptors, GABA-A; Structure-Activity Relationship; Zolpidem	2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013

Article

Year

Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.

Journal of medicinal chemistry, 2008, Nov-27, Volume: 51, Issue:22

Topics: Azabicyclo Compounds; Benzodiazepines; Binding Sites; Cell Line; Computer Simulation; Cysteine; DNA Mutational Analysis; Eszopiclone; GABA-A Receptor Agonists; Humans; Hydrogen Bonding; Ligands; Models, Chemical; Models, Molecular; Mutagenesis, Site-Directed; Piperazines; Pyridines; Receptors, GABA-A; Structure-Activity Relationship; Zolpidem

2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013